Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04741230 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigator Initiated, Prospective Study of Xenia Corneal Lenticule

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion dates: Apr 1, 2026 to Dec 1, 2026v16
  2. Minor Re-verified, no change to tracked fieldsv15
  3. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 17, 2024 to May 15, 2024
    • Site details revised
    v14
  4. Notable Start date: Apr 15, 2024 to May 17, 2024v13
  5. Notable Start date: Mar 1, 2024 to Apr 15, 2024
    • Primary completion date: Mar 1, 2026 to Apr 1, 2026
    • Study completion date: Jun 1, 2026 to Apr 1, 2026
    v12
Show 10 earlier versionsHide 10 earlier versions
  1. Notable Start date: Dec 1, 2023 to Mar 1, 2024
    • Primary completion date: Dec 1, 2025 to Mar 1, 2026
    v11
  2. Notable Primary completion date: Jun 1, 2023 to Dec 1, 2025
    • Start date: Dec 30, 2022 to Dec 1, 2023
    • Study completion date: Jun 1, 2023 to Jun 1, 2026
    v10
  3. Notable Start date: Aug 30, 2022 to Dec 30, 2022v9
  4. Notable Start date: Jun 30, 2022 to Aug 30, 2022v8
  5. Notable Start date: May 1, 2022 to Jun 30, 2022v7
  6. Notable Start date: Jan 1, 2022 to May 1, 2022v6
  7. Notable Start date: Oct 1, 2021 to Jan 1, 2022v5
  8. Notable Start date: Jun 1, 2021 to Oct 1, 2021v4
  9. Notable Start date: Apr 1, 2021 to Jun 1, 2021
    • Primary endpoints revised (4)
    • Primary and study completion dates: Apr 1, 2023 to Jun 1, 2023
    v3
  10. Notable Primary endpoints revised (4)v2
  1. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cornea ectatic conditions such as keratoconus and post-LASIK (Laser In situ Keratomileusis) ectasia are disorders of the eye that are notorious for its uncontrolled progression over time, leading to loss of vision. There are valuable treatment options for controlling disease progression in mild to moderate stages of such disease. However in advanced cases and / or when contact lenses cannot be worn, surgery remains the only treatment option to rehabilitate vision. Most treatment options are highly invasive and represent significant risks. This study evaluates a novel corneal implant, Gebauer™ Lenticule to treat severe keratoconus or post-LASIK ectasia. This implant is derived from porcine collagen and intended for intra-stromal insertion. The Gebauer™ Lenticule is expected to improve the stability of the cornea while not impairing the vision. The procedure is an additive procedure after other treatment options have been exhausted. The procedure is reversible with removal of the implant (in the unexpected case of an adverse reaction), and vision may be restored to baseline. The purpose of this study is to evaluate how well the implant is tolerated, it's safety profile, and how effective this new treatment option is in the treatment of keratoconus or post-LASIK ectasia.
Trial Details
NCT Number NCT04741230
Lead Sponsor The Royal Wolverhampton Hospitals NHS Trust
Collaborators: Gebauer Company
Conditions
(from sponsor)
Keratoconus, Post-Laser Retinal Condition
Related terms Keratoconus
Enrollment 15 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov